

# Lipid Droplets Fuel Small Extracellular Vesicle Biogenesis

Géraldine C. Genard<sup>1\*</sup>, Luca Tirinato,<sup>1,2\*</sup> Francesca Pagliari<sup>1</sup>, Jessica Da Silva<sup>1</sup>, Alessandro Giammona<sup>3</sup>, Fatema Alquraish<sup>3</sup>, Marie Bordas<sup>4</sup>, Maria Grazia Marafioti<sup>1</sup>, Simone Di Franco<sup>5</sup>, Jeannette Janssen<sup>1</sup>, Daniel Garcia-Calderón<sup>1,6</sup>, Rachel Hanley<sup>1</sup>, Clelia Nistico<sup>1,7</sup>, Yoshinori Fukasawa<sup>8</sup>, Torsten Müller<sup>9,10</sup>, Jeroen Krijgsveld<sup>10,11</sup>, Matilde Todaro<sup>5</sup>, Francesco Saverio Costanzo<sup>7</sup>, Giorgio Stassi<sup>5</sup>, Michelle Nessling<sup>12</sup>, Karsten Richter<sup>12</sup>, Kendra K. Maass<sup>13</sup>, Carlo Liberale<sup>3#</sup>, Joao Seco<sup>1,6#</sup>

<sup>1</sup> Division of Biomedical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany

<sup>2</sup> Nanotechnology Research Center, Department of Experimental and Clinical Medicine, University of Magna Graecia, 88100 Catanzaro, Italy

<sup>3</sup> Biological and Environmental Science and Engineering, King Abdullah University of Science and Technology (KAUST), Saudi Arabia

<sup>4</sup> Division of Molecular Genetics, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany

<sup>5</sup> Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy

<sup>6</sup> Department of Physics and Astronomy, Heidelberg University, 69120 Heidelberg, Germany

<sup>7</sup> Department of Experimental and Clinical Medicine, University of Magna Graecia, 88100 Catanzaro, Italy

<sup>8</sup> Core Labs, King Abdullah University of Science and Technology (KAUST), Saudi Arabia

<sup>9</sup> German Cancer Research Center, DKFZ, 69120 Heidelberg, Germany

<sup>10</sup> Heidelberg University, Medical Faculty, 69120 Heidelberg, Germany

<sup>11</sup> Proteomics of Stem Cells and Cancer, German Cancer Research Center, 69120 Heidelberg, Germany

<sup>12</sup> Electron Microscopy Facility, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany

<sup>13</sup> Hopp-Children's Cancer Center Heidelberg (KiTZ), 69120 Heidelberg, Germany

\* These Authors contributed equally to the work.

# Corresponding Authors: Professor Carlo Liberale ([carlo.liberale@kaust.edu.sa](mailto:carlo.liberale@kaust.edu.sa))  
Professor Joao Seco ([joao.seco@dkfz.de](mailto:joao.seco@dkfz.de))

## Abstract

Despite an increasing gain of knowledge regarding small extracellular vesicle (sEV) composition and functions in cell-cell communication, the mechanism behind their biogenesis remains unclear. Here, we revealed for the first time that the sEV biogenesis and release into the microenvironment are tightly connected with another important organelle: Lipid Droplets (LD). We have observed

52 this correlation using different human cancer cell lines as well as patient-derived colorectal cancer  
53 stem cells (CR-CSCs). Our results showed that the use of external stimuli such as radiation, pH,  
54 hypoxia, or lipid interfering drugs, known to affect the LD content, had a similar effect in terms of  
55 sEV secretion. Additional validations were brought using multiple omics data, at the mRNA and  
56 protein levels. Altogether, the possibility to fine-tune sEV biogenesis by targeting LDs, could have  
57 a massive impact on the amount, the cargos and the properties of those sEVs, paving the way for  
58 new clinical perspectives.

59  
60 **Keywords: Lipid Droplets, Small Extracellular Vesicles, Exosomes, Irradiation, pH, Iron**  
61 **Metabolism, Rab, Hypoxia.**

## 62 **Significance Statement**

## 63 **Introduction**

64  
65  
66 In 2013 Professors James E. Rothman, Randy W. Schekman and Thomas C. Südhof were awarded  
67 with the Nobel Prize for their discoveries of machinery regulating vesicle traffic, a major transport  
68 system in human cells (1). Their and other groups' works highlighted the importance of intra- and  
69 extracellular vesicles (EVs) in the cell-cell communication and their ability to modulate the cellular  
70 microenvironment.

71  
72 Almost all mammalian cells produce EVs, defined as “lipid bilayer-enclosed extracellular  
73 structures” of different size and intracellular origin. EVs are characterized by their size, cell origin,  
74 molecular composition, and functions (2). Small extracellular vesicles (sEVs) are distinguished  
75 from other EV subtypes by their small size (30 - 200 nm) and their ability to travel along the blood  
76 and lymph streams to reach distant organs from their sites of origins. Since they carry intracellular  
77 content of donor cells (including DNA, RNA, proteins, and lipids), those sEVs influence the fate  
78 of acceptor cells (3, 4). Their roles have been described in many physiological and pathological  
79 conditions, such as cancer, cardiovascular disease, immune response, and regeneration (5). In a  
80 tumor context, cancer cell-derived sEVs are believed to be secreted in large amount, with the ability  
81 to remodulate the tumor microenvironment and the tumor progression through various mechanisms,  
82 including immune evasion(6), proliferation, invasion, or metastasis (5).

83 sEVs have two different subcellular origins, either endosomal or non-endosomal, making them  
84 heterogenous. In particular, sEVs of endosomal origin, so-called *exosomes*, are nanoparticles  
85 released through the fusion of multivesicular bodies (MVBs) (containing intraluminal vesicles  
86 (ILVs)) with the plasma membrane (2). The non-endosomal pathway generates sEVs devoid of  
87 CD63, CD81 and CD9 or sEVs enriched in ECM and serum-derived factors (7).

88 As all sEVs are shaped by lipids, we hypothesized that a potential common source builds up the  
89 surrounding membrane: either coming from the recycling of plasma membrane within the  
90 endosomal pathway or through a new source of phospholipids.

91 Lipid Droplets (LDs) have been considered as mere fat storage organelles for a long time, although  
92 important evidence could be traced back to the early 1960's (8). As of today, LDs are well  
93 recognized as fundamental cellular hubs involved in many physiological as well as pathological  
94 processes, including cancer (9, 10). Nevertheless, many open questions about their formation,  
95 composition and role remain to be fully elucidated.

96 LDs are spherical organelles, which are found in the cytoplasm, and in some cases, in the nucleus  
97 of all eukaryotic cells(11). They are characterized by a lipid-rich core (cholesterol esters (CEs) and  
98 triacylglycerols (TAGs)) surrounded by a phospholipid monolayer (12). Although the LD-protein  
99 repertoire is cell-specific and influenced by the methodology used for their isolation, to date, more  
100 than 150 specific LD-proteins have been detected in mammalian cells (13).

101 In addition to their role in membrane biosynthesis, LDs are very active organelles due to their  
102 continuous cycle of growth and consumption reflecting the cell status needs (13). In this regard,

103 during cell expansion and division (which require membrane enlargement and increased  
104 biosynthesis of phospholipids), the fatty acids stored as TAGs in the LD core are mobilized either  
105 by lipolysis or by lipophagy (13). This allows the cell to sustain several metabolic processes and  
106 membrane biosynthesis.

107 LDs were associated with numerous other functions. For example, LD accumulation protects cells  
108 from oxidative stress damage by sequestering free fatty acid (14). In the same context, LD increase  
109 is considered as a cancer stem cell marker in many tumors (15, 16) and as a cell signature for  
110 radioresistance (17). Moreover, a role for LDs in the immune system modulation has been also  
111 reported in colorectal cancer (18).

112 To carry out their multiple roles, LDs need to “interact” with other cellular players. To do so, they  
113 establish physical contact with several organelles, like the endoplasmic reticulum (ER),  
114 peroxisomes, lysosomes, mitochondria, and endosomes (13).


115 Several reports suggested a connection between the lipid incorporation into LDs and the  
116 intracellular vesicle formation (13, 19). Interestingly, it was seen that the adipose tissue, whose  
117 cells contain the largest amount of LDs, is responsible for the highest number of secreted sEVs  
118 (AdExos)(20). It was also shown that these lipid-filled AdExos are then used by macrophages as a  
119 source of lipids (21).

120 Based on this evidence, we decided to investigate the potential connection between LDs and sEVs.  
121 To this purpose, we used different commercial human cancer cell lines (colon, lung, pancreatic and  
122 breast cancer cells) as well as patient-derived CR-CSCs. By using several means, we analyzed the  
123 impact of modulating the LD content on sEVs and the connection LDs – sEVs. Indeed, we adopted  
124 different external stimuli (such as distinctive pH, oxygen concentration, and ionizing radiations) or  
125 used LD inhibitors and silencing of Ferritin Heavy Chain 1 (FTH1), since its role in the LD  
126 formation has been already shown (17).

## 127 128 **Results**

### 129 **The number of LDs strongly correlates with the release of sEVs in colorectal cancer cell lines.**

130 To evaluate if there is a possible connection between cellular LD content and sEV release, we first  
131 compared both the number of LDs and the average amount of released sEVs per cell, in two  
132 different colorectal cancer cell lines, LoVo and HT29 (**Fig 1**). As shown by z-stack projections of  
133 confocal microscopy images and by the associated LD quantification, HT29 contained significantly  
134 more LDs per cell than LoVo 72h after seeding (**Fig 1A**). In parallel, the released sEVs were studied  
135 for both cell lines 72 hrs after seeding. The sEV isolation protocol was used as described in (22) and  
136 pictured in **Fig S1A**. The purity of the sEV samples was validated by observing the presence of  
137 exosomal markers (CD81, Tsg101 and CD63) as well as the absence of Golgi (GM130),  
138 endoplasmic reticulum (Calnexin), mitochondrial (Cytochrome C) and plasma membrane and  
139 cytoplasmic (Enolase 1) markers in the sEV preparations. In accordance with the literature (23), we  
140 found the presence of Hsc-70 both in the cellular and sEV fractions, with a predominance for the  
141 cellular fraction (**Fig S1B**). As expected, EM analysis of the sEV preparations showed a size  
142 ranging from 30 nm to 200 nm for the isolated sEVs (**Fig 1B**). Similarly, we could determine the  
143 number of particles and their size by using Nanoparticle Tracking Analysis (NTA). The average  
144 size of particles peaked at 148 nm for LoVo cells and 133 nm for HT29 cells (**Fig S1C**). The NTA  
145 measurement (**Fig 1C**) and the protein quantification (**Fig S1D and S1E**) also confirmed a higher  
146 amount of sEVs released per cell for HT29 as compared to LoVo cells. We next aimed to identify  
147 exosomal markers by western blotting to confirm the higher number of sEVs released by HT29 cell  
148 line. By loading the same volume of each sample, we observed that exosomal markers (CD9, CD63,  
149 CD81 and hsc-70) were significantly more expressed in the sEV fractions collected from HT29  
150 than LoVo cell line (**Fig 1D**). Finally, as the number of LDs might be heterogeneous among the  
151 same cell line, we sorted HT29 cells based on their LD content.



153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177


**Figure 1. Analysis of LD content and sEV release in LoVo and HT29 colorectal cancer cell lines.** **A)** HT29 and LoVo cell lines were stained with LD540 (green) for LDs and DAPI (blue) for nuclei and imaged at the confocal microscope with a 100X objective (Leica Microsystems; Concord, Ontario, Canada). The pinhole was set for a slice thickness of 17.4  $\mu\text{m}$ , with an interval between slices of 0.9  $\mu\text{m}$ . Z-projection of the z-stack acquisitions is shown (left). Displayed are the merged images of the LD540 and DAPI staining from one independent experiment (Scale bar, 20  $\mu\text{m}$ ). The graph represents the changes in LD content for LoVo and HT29 cell lines. Images were analyzed using ImageJ for mean of LDs per cell. Comparisons between groups are shown with corresponding p-values (unpaired Student's t-test). Error bars represent the means  $\pm$  SD. n=1 (LoVo: N = 532 cells; HT29: N = 4645 cells). **B)** High-resolution transmission electron micrograph of sEVs isolated from HT29 media taken with Zeiss EM 910 at 100 kV. Uranyl acetate negative staining reveals that purified sEVs have a cup-shaped morphology enclosed by a lipid bilayer. The diameter of sEVs is around 90–100 nm. The presented image has a magnification of 16000 x in TEM mode. The size bars on the image represent 250 nm. **C)** Ratio of particle number per cell for the sEV fractions (F2) released by LoVo and HT29 by nanoparticle tracking analysis (NTA). Comparisons between groups are shown with corresponding p-value. Unpaired students t-test was performed. Error bars represent the means  $\pm$  SD from three independent experiments. **D)** Western blot for the sEV pellets (100K) obtained by differential ultracentrifugation combined with SEC for LoVo and HT29 cells. The same sample volume (19.5  $\mu\text{L}$ ) was loaded onto the 10% acrylamide gel. The results presented here are representative of three independent experiments. The intensity of the bands corresponding to HT29 proteins was normalized by the intensity of the LoVo proteins band. Unpaired students t-test was performed. Error bars represent the means  $\pm$  SD from three independent experiments. **E)** HT29 cells were stained with LD540 for LDs and sorted based on their 10% brightest and 10% dimmest LD540 fluorescence values. Thereafter, sorted HT29 cells were spun on slides using cytospin and were directly fixed, permeabilized and stained for CD63 (MVBs) and DAPI (nuclei). Cells were then imaged at the confocal microscope with a 100X objective (Leica Microsystems; Concord, Ontario, Canada). Displayed are the merged images of the CD63 and DAPI stainings (Scale bar, 20  $\mu\text{m}$ ). \*  $\leq$  0.05; \*\*  $\leq$  0.01; \*\*\*  $\leq$  0.001 and \*\*\*\*  $\leq$  0.0001.

Thereafter, the multivesicular bodies (MVBs) were assessed by confocal microscopy. The images indicated a high MVB numbers for the HT29 LD<sup>High</sup> fraction in comparison to the HT29 LD<sup>Low</sup>

178 counterpart (**Fig 1E**). Altogether, these results suggest that the intracellular LD content followed  
 179 the same trend as the released sEVs.

## 180 **Inhibition of LD metabolism reduces sEV release**

181 Thereafter, we decided to target LD biosynthesis in HT29 cells by using two lipid inhibitors  
 182 affecting two different steps of the LD biogenesis (**Fig 2A**).




183 **Figure 2. LD content inhibition reduces sEV release** **A**) Representation of the mechanism of action for Triacsin C and PF-  
 184 06424439. **B**) HT29 cells control or treated, either with 10  $\mu$ M Triacsin C or 30  $\mu$ M PF-06424439 for 72 hrs, were stained with  
 185 LD540 (green) for LDs and DAPI (blue) for nuclei and imaged at the confocal microscope with a 100X objective (Leica  
 186 Microsystems; Concord, Ontario, Canada). The pinhole was set for a slice thickness of 17.4  $\mu$ m, with an interval between slices of  
 187 0.9  $\mu$ m. Z-projection of the z-stack acquisitions is shown (left). The merged images of the LD540 and DAPI staining from one  
 188 independent experiment are displayed (Scale bar, 20  $\mu$ m). The graph represents the changes in LD content for HT29 cell line treated  
 189 or not with one of the two inhibitors used in this experiment. Images were analyzed using ImageJ for mean LDs per cell. Comparisons  
 190 between groups are shown with corresponding p-values (unpaired Student's t-test). Error bars represent the means  $\pm$  SD. n=1 (HT29  
 191 CTL Triacsin C: N = 575 cells; HT29 treated with Triacsin C: N = 430 cells; HT29 CTL PF: N = 860 cells; HT29 treated with PF-  
 192 06424439: N = 1083 cells). **C**) Ratio of particle number per cell for sEV fractions (F2) released by HT29 control or treated with LD  
 193 inhibitors using NTA. Unpaired students t-test was performed. Error bars represent the means  $\pm$  SD from three independent  
 194 experiments. **D**) Western blot for the sEVs pellets (100K) obtained by differential ultracentrifugation combined with SEC for HT29  
 195 cells control or treated, either with Triacsin C 10 $\mu$ M or PF-06424439 30  $\mu$ M. The same sample volume (19.5  $\mu$ L) was loaded onto  
 196 the 10% acrylamide gel. The results presented here are representative of three independent experiments. \*  $\leq$  0.05; \*\*  $\leq$  0.01; \*\*\*  $\leq$   
 197 0.001 and \*\*\*\*  $\leq$  0.0001, ns = not significant.

198 The first drug acts as an inhibitor of long fatty acetyl-CoA synthetases (Triacsin C), while the  
 199 second one blocks the glycerolipid synthesis (PF-06424439). Triacsin C and PF-06424439 were  
 200 used at a concentration of 10  $\mu$ M and 30  $\mu$ M respectively. The choice of the inhibitor concentrations  
 201 was made based on the literature for Triacsin C (18) and on the evaluation of LD and sEV numbers  
 202 per cell for PF-06424439. Both inhibitors induced a cellular LD number reduction 72 hrs after  
 203 incubation, as shown by confocal analysis and the associated quantification (**Fig 2B**). The LD  
 204 decrease was correlated to a drop of sEV released in the supernatant by HT29 cells (**Fig 2C**) and to

205 a reduction of the protein concentration within the sEV fraction (**Fig S2A**). In addition, a lower  
206 protein expression of exosomal markers (CD9, CD63, CD81 and hsc-70) as shown in **Fig 2D**, was  
207 observed 72 hrs after incubation with both inhibitors (**Fig 2D**). A quantification of exosomal marker  
208 expression was performed on 3 independent experiments emphasizing the difference between the  
209 control and the treated conditions (**Fig S2B**).  
210 Altogether, those results strengthen the connection between LDs and sEVs.

### 211 **Iron metabolism supports the connection between LDs and sEVs**

212 It is now quite well established that there is an interplay between the iron and the lipid metabolisms.  
213 In a previous work (17), we demonstrated that Ferritin Heavy chain (FTH1) – a key enzyme involved  
214 in cytoplasmic iron storage and redox homeostasis – regulated the cellular LD content. Therefore,  
215 we thought to use the same experimental system, based on short hairpin RNA targeting FTH1  
216 (shFTH1) or scrambled RNA (shRNA) in the MCF7 cell line, to evaluate the sEV biogenesis. First,  
217 we collected proteins from MCF7 shRNA and MCF7 shFTH1 to conduct a full proteome analysis.  
218 From this analysis, 543 proteins were found to be upregulated (Log2 Fold change > 1.2) and 770  
219 proteins downregulated (Log2Fold < 0.833) in MCF7 shFTH1 cells (**Fig 3A**). We then confirmed  
220 that metabolic pathways, including small molecule metabolic processes and cellular catabolic  
221 processes, were downregulated (**Fig S3A**) in MCF7 shFTH1 cells. In addition, the expression of  
222 proteins involved in adipogenesis, fatty acid metabolism as well as lipoprotein and cholesterol  
223 synthesis was mostly downregulated in MCF7 shFTH1 cells (**Fig S3B**). In particular, 31 proteins  
224 involved in the lipid metabolism were upregulated while 46 proteins were downregulated in the  
225 MCF7 shFTH1 cell line. Using String and Cytoscape software, we found that the “extracellular  
226 vesicle” pathway was downregulated, among others, in MCF7 shFTH1 cells (**Fig 3B**). A closer  
227 look to the exosomal pathway highlighted that 62.7% of proteins related to the exosomal pathway  
228 were downregulated in MCF7 shFTH1 cells as compared to the MCF7 shRNA ones (**Fig 3C**). In  
229 accordance with these results, NTA analysis emphasized fewer sEVs/cell released from MCF7  
230 FTH1 cells as compared to MCF7 shRNA cells (**Fig 3D**). By analyzing the protein expression of  
231 exosomal markers (Annexin V, Flotillin-1, CD81 and CD9) on the same sEV sample volume, we  
232 evidenced a lower expression of those markers in MCF7 shFTH1 than in MCF7 shRNA cells (**Fig**  
233 **3E**). The proteomic results strengthen this outcome, as the expression of almost all exosomal  
234 markers was downregulated in MCF7 shFTH1 cells as compared to MCF7 shRNA ones (**Fig 3F**).  
235 Altogether, these results confirmed that sEV amount is directly correlated to the cellular LD content  
236 and that iron metabolism is upstream from the LD-sEV connection.



237

238 **Figure 3. Iron metabolism supports the connection between LD and sEVs** **A**) Violin plot depicting the ratio of Log<sub>2</sub> Fold for  
 239 MCF7 shFTH1/MCF7 shRNA. The proteins for which the expression was highly upregulated (green) or highly downregulated (red)  
 240 were annotated on the plot **B**) Cellular processes upregulated (green) and downregulated (red) in MCF7 shFTH1 cells. **C**) Heatmap  
 241 of proteins belonging to the exosomal pathway. Representation of Log<sub>2</sub> Fold change values. **D**) Ratio of particle number per cell for  
 242 the sEV fraction (F2) released by MCF7 shRNA and MCF7 shFTH1 (F2), using NTA. Data are presented as means (n=1). **E**)  
 243 Western blot for the sEV pellets (100K) obtained by differential ultracentrifugation combined with SEC for MCF7 shRNA and  
 244 MCF7 shFTH1 cells. The same sample volume (19.5 μL) was loaded onto the 10% acrylamide gel. Annexin V, Flotillin 1, CD81  
 245 and CD63 exosomal markers were used. The results presented here are representative of one independent experiment. **F**) Expression  
 246 of main exosomal markers (Annexin A2 (ANXA2), CD9, flotillin 2 (FLOT2), CD63, flotillin 1 (FLOT1), CD81, Syntenin-1,  
 247 Annexin A5 (ANXA5), TSG101, HSP90B1 and Alix) is shown for MCF7 shRNA (blue) and MCF7 shFTH1 cells based on  
 248 proteomic data.

250

### 251 LD stimulation increases sEV biogenesis


252 It has been previously reported by our research group and others that X-ray radiation (17, 24) and  
 253 acidosis (pH 6.5) (25) promote an enrichment in cancer cells with high LD content (LD<sup>High</sup>). Since

254 the LD inhibition led to a decrease of sEV release, we then decided to evaluate the LD-sEV  
255 connection in a context of LD stimulation. We therefore studied the effect of pH variation on MCF7  
256 and H460 cell lines. Both cell lines were incubated with neutral pH (7.4) or in acidic (pH 6.5)  
257 conditions for 72 hrs. Afterward, the number of LDs per cell was assessed by confocal microscopy.  
258 We confirmed a higher number of LDs/cell in acidosis when compared to neutral media for both  
259 cell lines (**Fig 4A**). The isolation of sEVs revealed a higher number of particles released per cell  
260 (**Fig 4B**) and a higher protein concentration (**Fig S4A**) in low pH conditioned media. In line with  
261 these results, the expression of exosomal markers (CD63, CD9, CD81 and hsc-70) on sEVs isolated  
262 from acidic condition was more elevated than the neutral one (**Fig 4C and S4B**). The comparison  
263 between the two pH settings was carried out using the same sEV sample volume.  
264 The same approach was used to study the radiation effect. In our previous work, we showed that  
265 cancer cells surviving to 6 Gy X-rays were characterized by an increase of the LD content 72 hrs  
266 after irradiation (17, 24). Starting from this premise, we confirmed those data in H460 and MCF7  
267 cells and extended the study to the Panc01 cell line using either confocal imaging or flow cytometry  
268 (**Fig 4D, 4G and S4C**). PI was used to make sure PI<sup>+</sup> cells were not considered in the flow  
269 cytometry analysis. However, since the supernatant was changed every 24h and the PI<sup>+</sup> cells was  
270 very low (2.37%), we estimated that dead cells were washed away at the moment of the analysis  
271 (confocal microscopy or flow cytometry). Particle number and analysis of the exosomal marker  
272 expression (CD63, CD9, CD81 and hsc-70) demonstrated that irradiation treatment was also able  
273 to increase the sEV secretion (**Fig 4 E, 4F and S4D**). Interestingly, the cellular LD content increased  
274 proportionally to the radiation dose given to the cells (**Fig 4G and S4C**), and we observed the same  
275 trend for sEVs release (**Fig 4H**). EM also indicated the elevated number of sEVs collected from  
276 Panc01 and H460 72 hrs after 8 or 6 Gy X-rays respectively, as compared to the unirradiated  
277 conditions (**Fig 4I and S4F**). Interestingly, the particle size was similar between the sEVs isolated  
278 from irradiated or unirradiated cells (**Fig S4G**). In addition, the exosomal nature of Panc01-derived  
279 vesicles was demonstrated by an analysis of CD63<sup>+</sup> or Alix<sup>+</sup> multivesicular bodies (MVBs) in  
280 unirradiated (0 Gy) or irradiated (8 Gy) pancreatic cancer cells (**Fig 4J**). Moreover, we confirmed  
281 a clear correlation between cellular LD content and sEV biogenesis, as represented in **Fig 4K**. Since  
282 irradiation induces apoptosis and autophagy, it is important to consider that very small apoptotic  
283 bodies (100 – 1000 nm) and autophagic vesicles (40 – 1000 nm) could be co-isolated by differential  
284 ultracentrifugation combined with SEC (cut-off 200 nm) within the sEV pool. We therefore  
285 characterized the expression of AnnexinV and LC3 on sEVs isolated from Panc01 irradiated cells  
286 via western blot (**Fig S4F**) and ELISA (**Fig S4H**), showing an increase expression of those markers.  
287 However, an immunogold EM-staining also showed that 71.63% of sEVs were coated by gold-  
288 coupled anti-CD63 antibodies in irradiated condition (8 Gy) (**Fig 4L**). Altogether, while we cannot  
289 exclude a contamination of our sEVs with small apoptotic and autophagic vesicles after irradiation,  
290 we showed that the expression of CD63 on sEVs (western blot), the number of CD63<sup>+</sup> sEVs (EM)  
291 and the number CD63<sup>+</sup> MVBs (confocal microscopy) were increased after irradiation, meaning that  
292 a higher proportion of CD63<sup>+</sup> vesicles were released.  
293 Finally, to evaluate how irradiation could affect the exosomal cargos, exosomal proteins were  
294 extracted from sEVs either released by X-ray irradiated (6, 8 Gy) Panc01 cells or by their  
295 unirradiated counterpart. 431 sEV proteins, analyzed by Mass Spectrometry (**Fig 4M**), were  
296 downregulated while 566 proteins had an upregulated expression compared to the unirradiated  
297 conditions. Interestingly, a closer look to the lipid metabolism pathway (**Fig 4N**) led us to identify  
298 a higher expression of proteins involved in the lipid anabolism in sEVs derived from irradiated  
299 Panc01 as compared to the control condition, and especially after 6 Gy. The proteins, whose  
300 expression was downregulated, belonged to the lipid catabolism pathway, meaning that irradiation  
301 favors lipid biosynthesis while reducing lipolysis, in accordance with the increased LD formation.  
302 This also means that radiation, in addition to affect cellular LD content, regulates the lipid-related



303 sEV proteome. This is of high interest since the exosomal lipid proteome and lipid profile modulate  
304 the invasiveness of the recipient cells (26–28).  
305 Altogether, these results showed that variation in the tumor microenvironment (e.g., pH), or  
306 treatments, such as conventional radiation, can strongly stimulate LD biogenesis and modulate in  
307 the same way the interconnected sEV pathway.

308




310 **Figure 4. LD stimulation increases sEV biogenesis** **A** and **D**) Treated (pH 6.5 **A**) or 6 Gy **D**) and untreated (pH 7.4 **A**) or 0  
311 Gy **D**) H460 and MCF7 cells were stained with LD540 (yellow) for LDs and DAPI (blue) for nuclei and imaged at the confocal  
312 microscope with a 100X objective (Leica Microsystems; Concord, Ontario, Canada). n=1 (H460 pH 7.4, N=354 cells and pH 6.5,  
313 N=166 cells; MCF7 pH 7.4, N=93 cells and pH 6.5, N=33 cells; H460 IR 0 Gy and 6 Gy: N = 29 cells; MCF7 IR 0 Gy and 6 Gy: N  
314 = 50 cells). The pinhole was set for a slice thickness of 17.4  $\mu\text{m}$ , with an interval between slices of 0.9  $\mu\text{m}$ . Z-projection of the z-  
315 stack acquisitions is shown above. Displayed are the merged images of the LD540 and DAPI staining from one independent  
316 experiment (Scale bar, 20  $\mu\text{m}$ ). The graph represents the changes in LD content for MCF7 and H460 cell lines. Images were analyzed  
317 using ImageJ for mean LDs per cell. Comparisons between groups are shown with corresponding p-values (unpaired Student's t-  
318 test). Error bars represent the means  $\pm$  SD. **B** and **E**) Ratio of particle number per cell for the sEV fractions (F2) released by treated  
319 (pH 6.5 **B**) or 6 Gy **E**) and untreated (pH 7.4 **B**) or 0 Gy **E**) H460 or MCF7 cells, using NTA. Results from three independent  
320 experiments. Data are presented as means  $\pm$  SD. Comparisons between groups are shown with corresponding p-value (unpaired  
321 Student's t-test). **C** and **F**) Western blot for the sEVs pellets (100K) obtained by differential ultracentrifugation combined with  
322 SEC for H460 and MCF7. Same sample volume (19.5  $\mu\text{L}$ ) was loaded onto the 10% acrylamide gel. The results presented here are  
323 representative of three independent experiments. **G**) Panc01 cells, untreated and irradiated with 2, 4, 6 or 8 Gy, were stained with  
324 LD540 for LDs and PI for dead cells, and analyzed by flow cytometry. The graph represents the mean fluorescence intensity (MFI)  
325 (irradiated/unirradiated ratio). Comparisons between groups are shown with corresponding p-values (ANOVA I, Dunnett's post-  
326 test). Error bars represent the means  $\pm$  SD. n=3. **H**) Ratio of particle number per cell for sEV fraction (F2) released by Panc01  
327 irradiated with X-rays (0, 2,4,6 or 8 Gy). Results from three independent experiments. Data are presented as means  $\pm$  SD.  
328 Comparisons between groups are shown with corresponding p-value (ANOVA I, Dunnett's post-test). **I**) High-resolution  
329 transmission electron micrograph of sEVs isolated from unirradiated (0 Gy) or irradiated (8 Gy) Panc01 media taken with Zeiss EM  
330 910 at 100 kV. Uranyl acetate negative staining reveals that purified sEVs have a cup-shaped morphology enclosed by a lipid bilayer.  
331 The diameter of sEVs is around 90–100 nm. The presented image has a magnification of 16000 x in TEM mode. The size bars on  
332 the image represent 250 nm. **J**) Number of CD63+ or ALIX+ MVBs after irradiation (8 Gy) in Panc01 cells transfected CD63-  
333 pHLuorin or ALIX-mCherry plasmids (n=1) **K**) Pearson correlation on mean values was run to determine the relationship sEV and  
334 LD number. The correlation factor is 0.9907. **L**) Immunogold CD63 staining of Panc01-derived sEV in control condition and  
335 quantification of CD63-positive vesicles. The presented images were taken with Zeiss EM 910 at 100 kV and have a magnification  
336 of 16000 x in TEM mode. The size bars on the image represent 250 nm. **M**) Venn diagram of sEV proteomics analysis. Comparison  
337 of the proteins regulated for X-ray irradiation (6Gy and 8 Gy) with respect to the proteomics analysis of sEVs obtained  
338 from unirradiated Panc01 cells. **N**) Heatmap of proteins belonging to the lipid metabolism pathway. Representation of Log2 Fold  
339 change values for 6 and 8 Gy X-rays. \*  $\leq$  0.05; \*\*  $\leq$  0.01; \*\*\*  $\leq$  0.001 and \*\*\*\*  $\leq$  0.0001.

## 340 **Patient-derived colorectal cancer stem cells modulate their LD content and sEV release under** 341 **hypoxia**

342 It is known that LDs are considered as a functional marker for cancer stemness (10). Indeed, patient-  
343 derived CR-CSCs (**Fig 5A**) with a high LD content exhibited a higher tumorigenic potential (10,  
344 15). Moreover, it was shown that restricted oxygen conditions increased the CSC fraction and  
345 promoted the acquisition of a stem-like state (29). Considering this, we decided to study the  
346 influence of hypoxia on the LD-sEV interconnection in patient-derived CR-CSCs. By using  
347 confocal microscopy, we observed a higher number of LDs/cell when CR-CSCs were cultured in  
348 hypoxic conditions as compared to the normoxic state (**Fig 5B**). A parallel NTA analysis showed a  
349 higher number of sEVs released by CR-CSCs in hypoxia than in normoxic conditions (**Fig 5C**).  
350 The analysis of some exosomal markers also revealed a higher expression of CD9, CD63 and CD81  
351 in hypoxia than in normoxia when the same sEV sample volume was used for western blotting (**Fig**  
352 **5D**). Overall, we observed a clear correlation between LD content and sEV number with a Pearson's  
353 r coefficient of 0.870 ( $p < 0.01$ ) (**Fig 5E**).

354 Finally, to further evaluate the effect of hypoxia on the lipid metabolism and the exosomal pathway,  
355 we collected mRNA from the three different CR-CSCs in normoxia and hypoxia for a full  
356 transcriptome analysis. This led us to identify four upregulated pathways under hypoxia using  
357 String and Cytoscape: *i*) response to hypoxia; *ii*) extracellular matrix; *iii*) morphogenesis; *iv*)  
358 response to wounding (**Fig 5F**).

359



**Figure 5. Patient-derived colorectal cancer stem cells modulate their LD content and sEV release under hypoxia. A)** Schematic representation of CR-CSC isolation and culture. **B)** LD quantification in Colorectal Cancer Stem Cells (CR-CSCs) derived from patients with colorectal cancer. Treated (Hypoxia, N) and untreated (Normoxia, N) CR-CSCs (#4, #21, #8) were stained with BODIPY 493/503 for LDs (green) and DAPI (blue) for nuclei and imaged at the confocal microscope with a 100X objective (Leica Microsystems; Concord, Ontario, Canada). The pinhole was set for a slice thickness of 17.4  $\mu\text{m}$ , with an interval between slices of 0.9  $\mu\text{m}$ . Z-projection of the z-stack acquisitions is shown above. The merged images of the BODIPY and DAPI staining from three independent experiments are displayed (Scale bar, 20  $\mu\text{m}$ ). The graph represents the changes in LD content for the different CR-CSCs in hypoxia as compared to normoxia. Images were analyzed using ImageJ for mean LDs per cell. Comparisons between groups are shown with corresponding p-values (ANOVA I, Sidak post-test). Error bars represent the means  $\pm$  SD. \*  $\leq 0.05$ ; \*\*  $\leq 0.01$ ; \*\*\*  $\leq 0.001$  and \*\*\*\*  $\leq 0.0001$ , n=1. **C)** Ratio of particle number per cell for sEV fraction (F2) treated (Hypoxia, H) and untreated (Normoxia, N) (F2) released by CR-CSCs (#4, #21, #8). Results from one independent experiment. **D)** Western blot for the sEVs pellets (100K) obtained by differential ultracentrifugation combined with SEC for all CR-CSCs. The sample volume (19.5  $\mu\text{L}$ ) was loaded onto the 10% acrylamide gel. The results presented here are representative of one independent experiment. **E)** Pearson correlation on mean values was run to determine the relationship sEV and LD number for CR-CSC when LD content is either high (hypoxia) or low (normoxia). \*  $\leq 0.05$ ; \*\*  $\leq 0.01$ ; \*\*\*  $\leq 0.001$  and \*\*\*\*  $\leq 0.0001$ . **F)** Diagram of common upregulated pathways in all CR-CSCs culture under hypoxia (Cytoscape: Network specificity 6 genes, 0.4 k score, pValue adjusted  $< 0.05$ , log2 Fold change  $> 1.2$ ). **G)** Heatmap of proteins belonging to the exosomal pathway. Representation of Log2 Fold change values for the hypoxic condition as compared to the normoxic condition.

Downregulated genes belonged to *i)* tRNA pathway and *ii)* positive regulation of double strand break repair via homologous recombination (**Fig S5A**). This analysis also allowed us to confirm that many of the genes involved in the sEV pathway were upregulated (**Fig 5G**) similarly as the sEV number was modulated in the three CR-CSCs (**Fig 5B**). Interestingly, the expression of the genes involved in the lipid metabolic pathways was mainly upregulated under hypoxia, for all CR-CSCs (**Fig S5B**). In general, downregulated lipid metabolism-related genes were associated with lipid catabolism while the upregulated ones were associated with lipid anabolism. As expected, the hypoxia pathway was also upregulated in CR-CSCs cultured under hypoxic as compared to the normoxic conditions (**Fig S5 C**). Altogether, these results showed that the interconnection between LDs and sEVs was also present in patient-derived CR-CSCs cultured in hypoxic conditions.


389

## 390 **Discussion**

391 By modulating cellular LD amount, either through the inhibition of LD metabolism or the  
392 stimulation of LD biosynthesis in different cancer cell types, we report for the first time a tight  
393 correlation between the intracellular LD numbers and the sEV release. These findings were also  
394 validated in patient-derived CR-CSCs showing that hypoxia increased intracellular LDs as well as  
395 sEV biogenesis. In addition, multiple omics data confirmed, at the mRNA and protein levels, that  
396 LD and sEV pathways were similarly modulated and tightly connected.

397 It is becoming increasingly clear that LDs are not static organelles involved only in safely storing  
398 excessive and dangerous lipids, but they might play a major role as lipid sources for potential  
399 membrane-shaped vesicles. While the LD-sEV connection has never been shown so far, hypoxia  
400 (29, 31), low pH (6.5) (25, 32, 33), irradiation (17, 34), reactive oxygen species (ROS) (35, 36),  
401 high glucose consumption (37–39) and cellular senescence (40, 41), among others, have been  
402 shown to stimulate intracellular LD content as well as sEV release by cells. Several studies  
403 contributed to elucidate the mechanism behind the increased sEV biogenesis upon those  
404 stimulations. For example, cellular senescence and DNA damaging reagents or radiation were  
405 shown to stimulate sEV production through the activation of p53, at least partially (42).  
406 Intriguingly, p53 is known to activate the expression of several genes involved in endosome  
407 regulation, including Rab5B, Caveolin-1, TSAP6 and Champ4C (a subunit of ESCRT-III) (43, 44).  
408 In parallel, p53 was also demonstrated to have an impact on the lipid and iron metabolisms (45).  
409 Despite its multiple targets, p53 alone is not enough to fully elucidate the link between LDs on one  
410 side and the exosome pathway on the other side. Another example is the regulation of sEV release  
411 through ATM activation of the autophagic pathway in hypoxia (46). Hypoxia also triggers LD  
412 formation through HIF1a stabilization. However, despite its role in sEV biogenesis under hypoxic  
413 condition, the stabilization of HIF1a in normoxia was not sufficient to support its role in sEV  
414 production (47). Overall, while the link between autophagy and LDs has already been well  
415 established and characterized, little is known about how LDs could fuel sEV biogenesis. It is to  
416 note that the LD content modulation via acidosis, radiation or hypoxia is not as straightforward as  
417 LD inhibition and each of those stimulation cannot be claimed to be processes that only impact LD  
418 or sEVs as they have a global cell impact. However, all the experiments presented here, taken  
419 altogether, allowed us to establish a strong LD-sEV connection.

420 With our proteomic analyses, we identified proteins whose expression was modulated according to  
421 the LD content. A focus on the proteins involved in the exosomal pathway allowed us to evidence  
422 a potential role of Rab18, Rab1a, Rab5c and Rab7a in the interconnection between LDs and sEVs  
423 **(Figure 6; Table S1).**



**Figure 6.** STRING (v.11.5)-based interaction analysis of the proteins identified by mass spectrometry as upregulated in LD<sup>High</sup> content cells and downregulated in LD<sup>Low</sup> content cells. A focus on proteins involved in exosome and lipid metabolism allowed to evidence Rab18, Rab5c, Rab7a and Rab1a as key factors in the LD-sEV connection.

In particular, Rab18 knockout was shown to affect the LD growth and maturation, inducing fewer but bigger LDs (48, 49). While Rab18 does not seem to be involved in LD biogenesis, its role in connecting LD catabolism to the autophagic and endosomal pathway is more and more clear (48, 49). Interestingly, Rab18 KO cells showed an increased expression and phosphorylation of ATG2 A/B, ATG9A and ATG16L1, as a compensation to the limited lipid availability (48). In addition, since RAB3GAP1/2 controls the activity and the location of Rab18, its knockout was shown to affect the LD content in the same way as Rab18KO (48, 49). The activity and location of Rab18 on LDs is also controlled by another complex, COPI-TRAPP II (TRAPPC9/TRAPPC10). However, TRAPP II does not seem to play an essential role in the early secretory pathway (50). Finally, Rab18 was found on a sEV subtypes, for which the secretion is mediated by CHMP1A, an ESCRT-III protein (49).

Although the connection of other Rab proteins to the LD and sEV pathways was not extensively investigated, emerging roles of Rab1a, Rab5c and Rab7a in the sEV and LD pathway are recognized. For example, mutations on Rab18, but also Rab5, are known to induce Warburg Syndrome, characterized by the appearance of fewer but bigger LDs (52). Proteomic data published several years ago, also emphasized Rab1a, Rab5b, Rab7a and Rab18 as important players for the connection between LDs and endoplasmic membranes (53). Hypoxia was also shown to increase exosome release via Rab5a (54). In addition, Aromatase inhibitors, through the increased expression of Rab18, Rab5c and Rab7a, stimulated the exosome biogenesis (55). However, Rab18, Rab5a, Rab5c and Rab7a were observed on the ectosomes at a higher level than on the sEV/exosomes. On the contrary, Rab1a is more expressed on sEV/exosomes than ectosomes (56). Finally, the investigation of CD63 routes showed its interaction with Rab5 and Rab7 (57). Altogether, while the literature offers insights that support our hypothetical mechanism, further investigations are needed to fully elucidate the LD-sEV connection.

Iron level elevation is associated with ferroptosis, a type of controlled cell death. Interestingly, Ferritin plays a pivotal role in the Fe<sup>2+</sup> storage (58) and low amount of ferritin drives ferroptosis. Since lipid peroxidation induces ferroptosis (59), cells protect themselves by storing lipids within LDs. Therefore, resistance to ferroptosis is usually associated with LD accumulation. Another way

457 for the cells to deal with an elevated iron level is to promote its export, either through free secretion  
458 or via the exosome pathway when associated with ferritin. Indeed, high iron level can trigger CD63  
459 expression via the IRE-IRP pathway and promote the exosomal secretion of ferritin-associated iron  
460 (60). In the same context, prominin 2 also favored the exosomal transport of ferritin (61).  
461 Interestingly, our results showed that the FTH1 silencing reduced the LD content and the sEV  
462 biogenesis, which might increase the iron level and promoting the susceptibility to ferroptosis (58).  
463 Since the cells containing the highest LD content are adipocytes, it is also interesting to correlate  
464 the sEVs released by those cells. Remarkably adipocytes from obese mice released more exosomes  
465 than lean mice (21). In the same context, obesity is associated with a higher risk of carcinogenesis  
466 in several organs, including breast, prostate, colon, and liver (62). It also correlates with a faster  
467 progression of cancer disease and an increased mortality (27). Interestingly, it was also shown that  
468 the fatty acid oxidation (FAO)-related protein content of adipocyte-derived sEVs modified  
469 mitochondrial dynamics in recipient melanoma cells, therefore promoting melanoma migration and  
470 aggressiveness (63, 64). Similarly, adipocyte-derived exosomes, by transporting neutral lipids,  
471 induced an adipose-tissue macrophage phenotype in bone marrow. We showed in our previous  
472 publications that LD<sup>High</sup> cells were more radioresistant than LD<sup>Low</sup> ones (17, 24). In the present study,  
473 we showed that sEVs derived from irradiated cells acquired a stronger lipid biosynthesis profile.  
474 Further analyses will help to understand if the lipid-related protein profile of sEVs released upon  
475 irradiation also influences the aggressiveness and the metastatic state of targeted cancer cells. At  
476 least, it is already known that sEV release after irradiation induced migration and invasiveness in  
477 head and neck and breast cancer cells (65, 66).

478 In conclusion, the possibility to fine-tune sEV biogenesis by targeting LDs could have a vast effect  
479 on the amount, the cargos and therefore the properties of sEVs thus potentially having a huge impact  
480 in the clinics. Further investigations will also help to shed new light on the mechanistic phenomenon  
481 behind the LD-sEV interaction and, by consequence, how to turn these results into a future patient-  
482 tailored therapy.

## 485 STAR Methods

### 487 1. Cell Culture

488 Different human cancer cell lines, purchased from ATCC, were used in this study. Human colon  
489 adenocarcinoma cell lines HT-29 (HTB-38) and LoVo (CCL-229) were cultured in McCoy's 5A  
490 (Modified) Medium, GlutaMAX<sup>TM</sup> Supplement (1X) (Gibco-Thermo Fischer Scientific, USA; #  
491 36600-021) or Ham's F-12K (Kaighn's) Medium Nutrient Mix (1X) (Gibco-Thermo Fischer  
492 Scientific, USA; # 21127-022) respectively. Human breast adenocarcinoma cell line MCF7 (HTB-  
493 22) was cultured in Dulbecco's Modified Eagle Medium (DMEM) high glucose (1X) (Gibco-  
494 Thermo Fischer Scientific, USA; #11995-065). Human non-small-cell lung carcinoma (NSCLC)  
495 cell line NCI- H460 (HTB-177) was cultured in Roswell Park Memorial Institute (RPMI) 1640  
496 Medium (1X) (Gibco-Thermo Fischer Scientific, USA; #22400-089). Human pancreatic epithelioid  
497 carcinoma PANC01 (CRL-1469) cell line was cultured in RPMI 1640 Medium (1X) (Gibco-  
498 Thermo Fischer Scientific, USA; #22400-089). All media were supplemented with 10% (v/v) heat  
499 inactivated fetal bovine serum (FBS) (Gibco-Thermo Fischer Scientific, USA; #10500-064). Cells  
500 were maintained in an incubator 5% CO<sub>2</sub> atmosphere at 37°C. Cells were split when a confluence  
501 of 90% was reached. All cell line were routinely authenticated (Multiplex human Cell  
502 Authentication, DKFZ, Germany).

### 504 2. Isolation of Cancer Stem Cells from Patients

505 CR-CSCs were isolated from patients affected by colorectal cancer (CRC) who underwent surgical  
506 resection, in accordance with ethical policy of the University of Palermo Committee on Human

507 Experimentation. CR-CSC isolation and characterization were carried out as reported elsewhere  
508 (67).

509 Briefly, CRC samples, after being cut in small pieces, were grinded by surgical scissors at 37 °C  
510 for 30 min in DMEM medium supplemented with 10 mg/ml of hyaluronidase (Sigma) and 0.6  
511 mg/ml of collagenase (GIBCO). Cell pellets were, subsequently, cultured in a serum-free Ham's F-  
512 12 Nutrient Mix medium (Thermo Fisher Scientific) using ultra-low attachment cell culture flasks  
513 (Corning). CR-CSC samples #4, #8 and #21, growing as spheroids, were mechanically and  
514 enzymatically disaggregated by Accutase (Thermo Fisher Scientific), when reached 80% of  
515 confluency.

516 Short tandem repeat (STR) analysis using a multiplex PCR assay, including a set of 24 loci  
517 (GlobalFiler™ STR kit, Applied Biosystem, USA), was routinely used to authenticate CR-CSCs  
518 and compare them to the parental patient tissues.

519

### 520 **3. Cell Culture and Transfection**

521 Lentiviral transduced MCF7 were stably transduced with a lentiviral DNA containing either an  
522 shRNA that targets the 196–210 region of the FTH1 mRNA (sh29432) (MCF-7shFTH1) or a  
523 control shRNA without significant homology to known human mRNAs (MCF-7shRNA). MCF-7  
524 shRNA and MCF-7 shFTH1 were cultured in DMEM medium (Thermo Fischer Scientific)  
525 supplemented with FBS 10% (Thermo Fischer Scientific), puromycin 1 µg/ml (Sigma-Aldrich).  
526 Cells were maintained at 37°C in a humidified 5% CO<sub>2</sub> atmosphere.

527

### 528 **4. sEV-free FBS**

529 Fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA) was ultra-centrifuged at 100,000×g for 18  
530 hrs at 4 °C. FBS supernatant was then filtered through a 0.22 µm filter (Millipore, USA) and used  
531 for sEV-related experiments.

532

### 533 **5. Treatments (pH, irradiation, hypoxia, inhibitors)**

534 To collect sEVs, H460 (1.8x10<sup>6</sup>), MCF7 (1.0x10<sup>6</sup>), PANC01 (1.5 10<sup>6</sup>), HT29 (2.0x10<sup>6</sup>) and LoVo  
535 (3.0x10<sup>6</sup>) cells were seeded in their normal medium (penicillin/streptomycin free) in T75 cm<sup>2</sup> flasks  
536 (Greiner CELLSTAR) 24 hrs prior treatment.

537 In the case of LD staining, H460 (1.0x10<sup>5</sup>), MCF7 (1.0x10<sup>5</sup>), HT29 (1.0x10<sup>5</sup>) and LoVo (1.0x10<sup>5</sup>)  
538 cells were seeded onto 12 pre-autoclaved coverslips (Electron Microscopy Sciences, USA) in a 12-  
539 well cell culture plate (Greiner CELLSTAR) and cultured in their normal medium supplemented  
540 with 100U/ml penicillin/streptomycin (Thermo Fischer Scientific, USA; #15140122). For X-ray  
541 irradiation (6 Gy), 3.5x10<sup>5</sup> cells were seeded for both H460 and MCF7 cell lines while 1.0x10<sup>5</sup> cells  
542 were seeded in control groups.

543

#### 544 **5.1. pH Treatment**

545 24 hrs after seeding, H460 or MCF7 cells were divided in two groups: *i*) a control group, for which  
546 the medium was replaced with fresh adequate pH 7.4 medium; *ii*) a treated group, cultured with  
547 medium for which pH was adjusted to 6.5. The pH of both cell media was adjusted just prior the  
548 medium replacement to avoid any kind of pH variation due to oxidation. Treated cells were kept in  
549 culture for 72 hrs. Fresh medium was replaced every day for LD experiments.

550 To avoid the presence of exogenous sEVs in experiments intended to collect cancer cell- derived  
551 sEVs, cells were washed twice with Dulbecco's phosphate buffered saline (DPBS) (Sigma-Aldrich,  
552 USA; #8537) and sEV-free FBS media was used (penicillin/streptomycin free).

553

#### 554 **5.2. Irradiation Treatment**

555 24 hrs after seeding, samples with H460 or MCF7 cells were divided in two groups: *i*) a control  
556 group, unirradiated and *ii*) a treated group, irradiated with 6 Gy X-rays using a MultiRad 225kV



557 (Faxitron, Germany) irradiator. Treated cells were kept in culture for 72 hrs to select only  
558 radioresistant cells at the end of the incubation time. Fresh medium was replaced every day for LD  
559 experiments. For PANC01 and H460 cells, 2, 4, 6 or 8 Gy were also used.

560 As for pH treatment, cells were washed with DPBS, and media were supplemented with sEV-free  
561 FBS (penicillin/streptomycin free).

### 562 563 **5.3. Hypoxia Culturing Conditions**

564 All experiments in hypoxic conditions were conducted by culturing CR-CSCs in a three-gas  
565 incubator (Thermo Fisher) at 37°C with a 2% of Oxygen and with 5% CO<sub>2</sub> atmosphere for 72 hrs.  
566 LD staining and RNA-seq have been carried at the end of the incubation time keeping all samples  
567 in hypoxic conditions.

### 568 569 **5.4. Lipid Droplet Inhibition**

570 Two different LD inhibitors were here tested: PF-06424439 (a diacylglycerol acyltransferase 2  
571 (DGAT2) inhibitor; Saint Louis, MO, USA, CN-PZ0233) and Triacsin C (a long-chain fatty acyl  
572 CoA synthetase inhibitor) (Cayman Chemical, #10007448).

573 Both treatments were carried out for 24 hrs with 30 μM of PF-06424439 or 10 μM of Triacsin C.  
574 Drug solutions were prepared freshly for every replicates. As for other treatments, cells were  
575 washed with DPBS and media was supplemented with sEV-free FBS (penicillin/streptomycin free).

### 576 577 **6. FACS Sorting**

578 HT29 cells were detached with TrypLE™ Express (Gibco, USA, #12604013) and then centrifuged  
579 for 5 min at 300 g. Cells were thereafter stained with LD540 for 10 min at 37°C in the dark. Both  
580 samples were washed with DPBS three times to remove the excess of the dye and then resuspended  
581 in the sorting buffer (PBS Ca/Mg-free, BSA 0.5%, EDTA 2 mM and Hepes 15mM).

582 Two populations were then sorted based on the LD abundance using a FACSAria Fusion Cell sorter  
583 (BD Bioscience).

584 The 10% LD<sup>High</sup> (most bright) and 10% LD<sup>Low</sup> (most dim) cells were collected and, soon after were  
585 seeded on a coverslip using a cytospin centrifuge (Thermo Shandon Cytospin3, Marshall Scientific,  
586 USA). Cells were then fixed with 4% PFA and an anti-CD63 (NOVUS #NBP2-52225, Germany)  
587 was used at a 1/1000 dilution in PBS+BSA 1% for 2 hrs. Thereafter, a donkey anti-mouse IgG  
588 (H+L) Alexa Fluor 647 (Thermo Fisher #A-31571, USA), used at 1/2000 dilution in PBS+BSA 1%  
589 for 1hr allowed us to stain the MVBs within the cells. Finally, cells were stained with 1mg/mL  
590 Hoechst 33342 (Thermo Fisher Scientific, CN-H3570) for 20 min before being processed for the  
591 optical imaging acquisition.

### 592 593 **7. Immunofluorescence and confocal microscopy**

#### 594 Lipid Droplet Staining

595 LD variation among the different treatments was assessed by staining the investigated cell samples  
596 with two different dyes, depending on the experiment needs: LD540 and Bodipy 493/503 (Thermo  
597 Fisher, CN-D2191). Briefly, cells were seeded onto a coverslip and left in culture the time necessary  
598 for the experiment endpoints (72 hrs for irradiation, hypoxia and LD inhibition, while only 24 hrs  
599 for pH). When ready, cells were washed with DPBS, fixed with 4% PFA and then stained with 0.1  
600 mg/ml LD540 or 2 mM Bodipy, both in DPBS. The volumes of the staining solutions were kept  
601 constants for all the analyzed cell samples. Nuclei were stained with 1mg/mL Hoechst 33342  
602 (Thermo Fisher Scientific, CN-H3570).

#### 603 604 CD63 and Alix plasmid transfection for confocal microscopy

605 Plasmids mCherry-hAlix (plasmid#21504) and pCMV-Sport6-CD63-pHluorin (plasmid #130902)  
606 were purchased from Addgene. Cells were plated at a density of 7.5x10<sup>4</sup> onto glass coverslips in

twelve-well plates and allowed to grow in the incubator for 24h. Then the cells were irradiated (8Gy) and were immediately transfected with the plasmids encoding CD63 or Alix, using FuGENE HD reagent (Promega, E2311, USA) with a FuGENE HD:DNA ratio of 4:1. After 48h post transfection the cells were washed with DPBS, fixed with 4% PFA for 10 minutes and then stained with 1 mg/ml Hoechst 33342. The images were taken exactly as mentioned in the above paragraph.

### Confocal microscopy

Whole z-stacks images for the stained cells were taken by using a Zeiss LSM710 or Leica SP5 confocal microscope systems equipped with a 40x (lipid droplets) or 63x (multivesicular bodies, MVBs) oil immersion i-Plan Aplanochromat (numerical aperture 1.40) objectives. LD540 and Bodipy 493/503 were visualized using the 488 nm laser excitation and a 505-530 nm band-pass filter.

## **8. Lipid Droplet Staining for Flow Cytometry Analysis**

Briefly,  $1.5 \times 10^6$  cells were seeded into T75 cm<sup>2</sup> flasks (Greiner CELLSTAR) 24 hrs prior irradiation (2, 4, 6, 8 and 10 Gy) and left in culture for 72 hrs after irradiation. Cells were detached with TrypLE<sup>TM</sup> Express (Gibco, USA, #12604013) and then centrifuged for 5 minutes at 300xg. Cells were thereafter stained with 0.1 mg/ml LD540 for 10 min at 37°C in the dark. Samples were washed with DPBS three times in order to remove the excess of the dye and then resuspended in the sorting buffer (PBS Ca/Mg-free, BSA 0.5%, EDTA 2 mM and Hepes 15mM). PI (Sigma-Aldrich, #P4864, Germany) was used to stain dead cells. Finally, the samples were analyzed using a FACS Canto II (BD Biosciences, USA).

## **9. Differential Centrifugation and sEV Isolation by Size Exclusion Chromatography**

Collected supernatants were supplemented with 1 mM Phenylmethylsulfonyl Fluoride (PMSF – Serva, Germany; # 32395) and 100U/ml penicillin/streptomycin (Thermo Fischer Scientific, USA; #15140122) before being centrifuged at 300xg for 10 min at 4°C in a swing-out centrifuge to remove cellular debris. Resulting 2,000xg supernatants were transferred into ultracentrifugation tubes (Thin-wall, Polyallomer 38.5 ml tubes, Beckman Coulter, USA; #326823) and centrifuged at 100,000xg for 2 hrs at 4°C using a Beckman L8-55MV ultracentrifuge (Beckman Coulter GmbH, Krefeld, Germany) with a SW27 Swinging-Bucket Rotor. Resulting 100,000xg pellets were resuspended in 200 µL of 0.22-µm-filtered PBS. Size exclusion chromatography was then used to separate the sEVs from the contaminants (e.g., proteins), as previously reported (22).

Briefly, single qEV 35 nm columns (Izon, Christchurch, New Zealand) were allowed to reach room temperature for 30 min. The resuspended pellet fraction (200 µL) was added onto the column. As soon as the sample volume was taken up by the column, 0.22 µm-filtered PBS was added to the top of the column tube. The following fractions were collected: F0 (800 µL = void volume of the column) and F1 to F7 (200 µL each), according to the manufacturer's instructions.

## **10. Protein Extraction and Quantification (Cells and sEVs)**

**Bicinchonic Acid.** Protein concentration of cell samples was assessed employing Pierce<sup>TM</sup> BCA Protein Assay Kit (Thermo Fisher Scientific Inc., Waltham, MA, USA). Cells were lysed in 300 µL of 1x RIPA buffer (Abcam, Cambridge, UK) supplemented with Halt<sup>TM</sup> Protease Inhibitor Cocktail, EDTA-free (100X) (Thermo Fisher, USA; #78425) and Halt<sup>TM</sup> Phosphatase Inhibitor Cocktail, (100X) (Thermo Fischer, USA, #78428). Samples were incubated for 20 min on ice and then centrifuged at 17,000xg for 20 min at 4 °C. Resulting supernatants were subjected to BCA assay according to the manufacturer's instructions. Absorbance was assessed at 562 nm with the use of a plate reader.

**Qubit.** To determine the protein concentration of the isolated sEV samples, Qubit Protein Assay Kit (Life Technologies, USA) was used. SDS (Thermo Fisher Scientific, DE) was used to extract

657 proteins. Briefly, 0.8  $\mu$ L SDS 2% and 7.2  $\mu$ L sEV sample were added in labeled Qubit assay tubes  
658 and vortexed for 30 sec. The resulting samples were then processed according to the manufacturer's  
659 instructions. For the standards (Qubit<sup>TM</sup> protein standard #1, #2, #3), 0.8  $\mu$ L SDS 2% and 10  $\mu$ L  
660 standards were added to the corresponding labelled Qubit tubes.

## 661 **11. Nanoparticle Tracking Analysis (NTA)**

662 Particle quantification of sEV samples was performed via NTA using NanoSight LM10 equipped  
663 with a 405 nm laser (Malvern Instruments, Malvern, UK). For the NTA analysis, samples were  
664 diluted 1:250 in 0.22  $\mu$ m-filtered PBS. Camera level and detection threshold were set up at 13 and  
665 1.8, respectively. The absence of background was verified using 0.2  $\mu$ m-filtered PBS. For each  
666 sample, five videos of 40 sec each were recorded and analyzed using the NTA 3.0 software version  
667 (Malvern Instruments, Malvern, UK).

## 668 **12. Immunoblotting**

669 sEVs were lysed in RIPA Lysis and Extraction Buffer 10X (Cell Signaling Technology, USA  
670 #98010) for 20 min on ice. Per lane, 19.5  $\mu$ l of protein samples were loaded onto 10%  
671 polyacrylamide gels. Following SDS-PAGE and protein transfer, membranes were blocked in 5%  
672 bovine serum albumin in PBS-Tween 0.1%, and primary antibodies against CD63 (1:1,000, Novus  
673 # NBP2-42225), CD81 (1:1000, ProSci Inc., San Diego, CA, USA, #5195), CD9 (1:1000, Cell  
674 Signaling Technology, Danvers, MA, USA, #13174) and hsc-70 (1:1000 Santa Cruz # sc-7298)  
675 were used to detect sEV markers.

676 Calnexin (1:500, GeneScript, Piscataway, NJ, USA, #A0124040), Cytchrome C (1:750,  
677 GeneScript, Piscataway, NJ, USA, #A0150740), GM130 (1:1000, Cell Signaling Technology,  
678 Danvers, MA, USA, #12480) and Enolase 1 (ENO-1) (1:1000, Abgent, San Diego, CA, #AP6526c)  
679 were used in indicated dilutions in 5% BSA in PBS-Tween 0.1% when cell proteins were compared  
680 to sEV ones, in order to exclude possible contaminants in sEV fractions.

681 Either HRP-linked Goat anti-Rabbit (Cell Signaling, USA; #7074), HRP-linked Goat anti-Mouse  
682 (Cell Signaling, USA; #7076) or HRP-linked Goat anti-Mouse (Thermo Fisher Scientific, USA;  
683 #631462) were used as secondary antibodies. Signals were visualized after secondary antibody  
684 hybridization by chemiluminescence detection reagent (Bio-Rad Lab, Hercules, CA, USA,  
685 #1705061) with Amersham Imager 680 (GE Healthcare, USA).

## 686 **13. Electron Microscopy (EM)**

687 For negatives staining EM, sEV fractions (F2) were adsorbed onto pure carbon-coated EM-grids  
688 for 5 min, washed in aqua bidest and negatively stained with 1% aqueous uranyl acetate. For  
689 immuno-EM, sEV fractions were adsorbed on formvar-carbon-coated EM-grids. The incubation  
690 with primary antibody (anti-CD63, 1:1000, BD Pharmingen, USA, #556019) was performed after  
691 buffer wash and incubation with blocking agent (Aurion, Wageningen, The Netherlands). Protein  
692 A-Au was used as reporter (CMC, UMC Utrecht, The Netherlands, size of Au-grains 10nm).  
693 Micrographs were taken with a Zeiss EM 910 or EM 912 at 80 kV (Carl Zeiss, Oberkochen,  
694 Germany) using a slow scan CCD camera (TRS, Moorenweis, Germany).

## 695 **14. RNA Sequencing Analysis**

696 Total RNA was extracted by RNeasy Mini Kit (Qiagen) and mRNA libraries were prepared using  
697 TruSeq<sup>®</sup> Stranded mRNA Library Prep. Next-Generation Sequencing (NGS) technology (RNA-  
698 seq) was used to identify some vital biological processes and pathways involved in fatty acid  
699 modulation on CSCs cultured in Hypoxia and Normoxia. Illumina HiSeq 4000 and NovaSeq 6000  
700 were used to perform transcriptome sequencing. The reads were aligned to GRCh38/hg38 of the  
701 human genome using STAR version 2.6.1d. Alignments were validated using a combination of  
702 FastQC version 0.11.8, SAMtools version 1.9, and MultiQC version 1.7 (68, 69). Transcript  
703  
704  
705  
706

707 abundance estimation was further performed using Salmon version 0.14.1 followed by importing  
708 them at the gene level with tximport version 1.14.0 (70, 71). Subsequently, expression analysis at  
709 the gene level was conducted with DESeq2 version 1.26.0 (72). Targeted gene analysis of  
710 commonly known genes and MORPHEUS Versatile matrix visualization and analysis software  
711 were used to visualize the datasets as heat maps (Morpheus,  
712 <https://software.broadinstitute.org/morpheus>).

## 713 714 **15. Proteomic Analyses**

715 **Cells.** MCF7-shRNA and MCF7-shFTH1 cells were washed twice and then scraped into 2ml of  
716 cold PBS. Cells were then centrifuged at 300xg for 5 min. Each pellet was incubated with 1mL of  
717 1X Ripa Buffer (Cell Signaling) additioned with Halt<sup>TM</sup> Protease Inhibitor Single-Use Cocktail,  
718 (Thermo Fisher Scientific) and Halt<sup>TM</sup> Phosphatase Inhibitor Single Use Cocktail (Thermo Fisher  
719 Scientific), both diluted 1:100 for 10 min on ice. Lysates were then sonicated (40% amplitude, 10  
720 s/cycle; 3 cycle; 4°C) and incubated for 15 min on ice. 100ml of Benzonase 2,75 U/ml (Millipore-  
721 Novagen) was added to lysates, incubated in ice for 10 min and then centrifuged at 2,500xg for 30  
722 min at 4°C. The supernatants were collected. Protein concentration was measured by BCA Protein  
723 assay kit (Thermo Fisher Scientific) at 562 nm.

724 **sEVs.** The protein quantification was performed with Qubit assay as described in section 10 (protein  
725 quantification).

726 **Sample Processing.** Samples were thawed and extensively vortexed before proceeding.  
727 Subsequently, for each sample, 10 µg protein were processed in a 1 µg/ 3 µL concentration in 1 %  
728 SDS and 100 mM ammonium bicarbonate (ABC, Sigma-Aldrich). In brief, 10 mM TCEP, 40 mM  
729 chloroacetamide (CAA), 100 mM ABC, and 1x protease inhibitor cocktail (PIC, cOmplete, Sigma-  
730 Aldrich) were added to each sample, followed by incubation at 95°C for 5 minutes. Protein binding  
731 to Sera-Mag Speed Beads (Fisher Scientific, Germany) was induced by increasing the buffer  
732 composition to 50% acetonitrile (ACN, Pierce – Thermo Scientific). The bead stock was prepared  
733 as follows: 20 µL of Sera-Mag Speed Beads A and 20 µL of Sera-Mag Speed Beads B were  
734 combined and rinsed with 1x 160 µL ddH<sub>2</sub>O, 2x with 200 µL ddH<sub>2</sub>O, and re-suspended in 20 µL  
735 ddH<sub>2</sub>O for a final working stock of which 2 µL were added per sample. The autoSP3 protein clean-  
736 up was performed with 2x ethanol (EtOH, VWR International GmbH, Germany) and 2x ACN  
737 washes. Reduced and alkylated proteins were digested on-beads and overnight at 37°C in a lid-  
738 heated PCR cyler (CHB-T2-D ThermoQ, Hangzhou BIOER Technologies, China) in 100 mM  
739 ABC with sequencing-grade modified trypsin (Promega, USA). Upon overnight protein digestion,  
740 each sample was acidified to a final concentration of 1% trifluoroacetic acid (TFA, Biosolve  
741 Chimie). MS injection-ready samples were stored at -20°C.

742 **Data Acquisition and Processing.** For the data acquisition a timsTOF Pro mass spectrometer  
743 (Bruker Daltonics) was equipped with an Easy nLC 1200 system (Thermo). An equivalent of 200  
744 ng protein per sample was injected using the following method: peptides were separated using the  
745 Easy nLC 1200 system fitted with an analytical column (Aurora Series Emitter Column with CSI  
746 fitting, C18, 1.6 µm, 75 µm x 25 cm) (Ion Optics). The outlet of the analytical column with a captive  
747 spray fitting was directly coupled to a timsTOF Pro (Bruker) mass spectrometer using a captive  
748 spray source. Solvent A was ddH<sub>2</sub>O (Biosolve Chimie), 0.1% (v/v) FA (Biosolve Chimie), and  
749 solvent B was 100% ACN in dH<sub>2</sub>O, 0.1% (v/v) FA. The samples were loaded at a constant pressure  
750 of 800 bar. Peptides were eluted via the analytical column at a constant flow of 0.4 µL per minute  
751 at 50°C. During the elution, the percentage of solvent B was increased in a linear fashion from 2  
752 to 17% in 22.5 minutes, then from 17 to 25% in 11.25 minutes, then from 25 to 37% in 3.75 minutes,  
753 and from 37% to 80% in a further 3.75 minutes. Finally, the gradient was finished with 3.75 minutes  
754 at 80% solvent B. Peptides were introduced into the mass spectrometer via the standard Bruker  
755 captive spray source at default settings. The glass capillary was operated at 1600 V and 3 L/minute  
756 dry gas at 180°C. Full scan MS spectra with mass range m/z 100 to 1700 and a 1/k0 range from

0.85 to 1.3 V\*s/cm<sup>2</sup> with 100 ms ramp time were acquired with a rolling average switched on (10x). The duty cycle was locked at 100%, the ion polarity was set to positive, and the TIMS mode was enabled. The active exclusion window was set to 0.015 m/z, 1/k<sub>0</sub> 0.015 V\*s/ cm<sup>2</sup>. The isolation width was set to mass 700-800 m/z, width 2 – 3 m/z and the collision energy to 1/k<sub>0</sub> 0.85-1.3 V\*s/cm<sup>2</sup>, energy 27- 45 eV.

The resulting raw files were searched using MaxQuant version 2.0.3.0 using the default settings unless otherwise stated. Label-free quantification (LFQ) and intensity-based absolute quantification (iBAQ) were applied using the default settings. Matching between runs was enabled. The resulting proteinGroups and peptide tables were further analyzed using matrixQCvis and R.

Protein analysis of commonly known proteins was performed using STRING (<https://string-db.org>; v.11.5) and cytoscape (v. 3.9.1).

## 16. Statistical Analysis

**Image analysis:** Twelve-bit z-stack images were acquired and post-processed for the LD quantification as reported elsewhere (17). Briefly, the background was subtracted from all images using ImageJ's Rolling ball radius tool. After that, all images were processed with Gaussian filter, thresholded and segmented with Find Maxima tool. At this point, processed images were analyzed with Analyze Particle tools. The whole image processing was set up automatically thanks to the in-house developed Fiji macro generously provided by Dr. Damir Kronic. Statistical analysis was performed by Student's t-test with unequal variances. Only p-values below 0.05 were considered statistically significant between two groups.

**sEVs:** Results of the functional analysis were analyzed for statistical significance with GraphPad PRISM 8.0 software (GraphPad Software, San Diego, CA, USA), using unpaired t-test or one-way analysis of variance (ANOVA), followed by Tukey's multiple comparisons. The differences between means were considered significant if  $p \leq 0.05$ . The results are expressed as the means  $\pm$  standard deviation.

## Acknowledgements

We gratefully acknowledge the imaging and FACS Facilities at the DKFZ and the CoreLab Genomic Facility at KAUST for their prompt and precious support. We also are grateful to the Dr. Sebastian Dieter's group for the continuous access to the ultracentrifuge.

Carlo Liberale and Joao Seco acknowledge funding from King Abdullah University of Science and Technology, Grant Award Number: OSR-CRG2018-3747.

Luca Tirinato has received funding from AIRC and from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Skłodowska-Curie grant agreement n. 800924.

Jeannette Jansen was supported by grants of the German-Israeli Helmholtz Research School in Cancer Biology – Cancer Transitional and Research Exchange Program (Cancer-TRAX).

Daniel Garcia-Calderon was funded by the Graduate School Scholarship Programme, 2019 from the DAAD.

## Author Contributions

Geraldine C. Genard: Conceptualization, Methodology, Data Curation, Validation, Formal Analysis, Investigation, Writing Original Draft. Luca Tirinato: Conceptualization, Methodology, Data Curation, Validation, Formal Analysis, Investigation, Writing Original Draft and Funding Acquisition. Francesca Pagliari, Jessica Da Silva, Alessandro Giammona, Fatema Alquraish, Marie Bordas and Maria Grazia Marafioti: Methodology and Investigation. Simone Di Franco, Jeanette Jansen, Daniel Garcia, Rachel Hanley, Clelia Nisticò, Yoshinori Fukusawa Torsten Müller and Jeroen Krijgsveld: Data Curation. Matilde Todaro, Francesco Saverio Costanzo, Giorgio Stassi and

807 Kendra K Mass: Supervision, Investigation and Funding Acquisition. Michelle Nessling and  
808 Karsten Richter: TEM Data Curation and Validation. Carlo Liberale: Project Supervision, Funding  
809 Acquisition, Data Curation and Draft Revision. Joao Seco: Conceptualization, Methodology,  
810 Funding Acquisition, Project Supervision and Draft Revision.

811

## 812 Declaration of Interest Statement

813 All Authors declare no conflict of interest.

814

815

## 816 References

- 817 1. J. S. Bonifacino, Vesicular Transport Earns a Nobel. *Trends Cell Biol* **24**, 3 (2014).
- 818 2. M. Mathieu, L. Martin-Jaular, G. Lavieu, C. Théry, Specificities of secretion and uptake of exosomes and  
819 other extracellular vesicles for cell-to-cell communication. *Nat Cell Biol* (2019)  
820 <https://doi.org/10.1038/s41556-018-0250-9>.
- 821 3. D. K. Jeppesen, *et al.*, Reassessment of Exosome Composition. *Cell* **177**, 428–445.e18 (2019).
- 822 4. M. Yáñez-Mó, *et al.*, Biological properties of extracellular vesicles and their physiological functions. *J*  
823 *Extracell Vesicles* **4**, 1–60 (2015).
- 824 5. R. Kalluri, V. S. LeBleu, The biology, function, and biomedical applications of exosomes. *Science* (1979)  
825 (2020) <https://doi.org/10.1126/science.aau6977>.
- 826 6. M. Poggio, *et al.*, Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.  
827 *Cell* **177**, 414–427.e13 (2019).
- 828 7. J. Kowal, *et al.*, Proteomic comparison defines novel markers to characterize heterogeneous populations of  
829 extracellular vesicle subtypes. *Proc Natl Acad Sci U S A* **113**, E968–E977 (2016).
- 830 8. M. H. Aboumr, R. C. H O R N, G. Fine, “LIPID-SECRETING MAMMARY CARCINOMA Report of a  
831 Case Associated with Paget’s Disease of the N i p p l e.”
- 832 9. A. L. S. Cruz, E. de A. Barreto, N. P. B. Fazolini, J. P. B. Viola, P. T. Bozza, Lipid droplets: platforms with  
833 multiple functions in cancer hallmarks. *Cell Death Dis* **11** (2020).
- 834 10. L. Tirinato, *et al.*, An Overview of Lipid Droplets in Cancer and Cancer Stem Cells. *Stem Cells Int* (2017)  
835 <https://doi.org/10.1155/2017/1656053>.
- 836 11. K. Softysik, Y. Ohsaki, T. Tatematsu, J. Cheng, T. Fujimoto, Nuclear lipid droplets derive from a lipoprotein  
837 precursor and regulate phosphatidylcholine synthesis. *Nat Commun* **10** (2019).
- 838 12. H. F. Hashemi, J. M. Goodman, The life cycle of lipid droplets. *Curr Opin Cell Biol* **33**, 119–124 (2015).
- 839 13. J. A. Olzmann, P. Carvalho, Dynamics and functions of lipid droplets. *Nat Rev Mol Cell Biol* **20**, 137–155  
840 (2019).
- 841 14. A. P. Bailey, *et al.*, Antioxidant Role for Lipid Droplets in a Stem Cell Niche of *Drosophila*. *Cell* **163**, 340–  
842 353 (2015).
- 843 15. L. Tirinato, *et al.*, Lipid droplets: A new player in colorectal cancer stem cells unveiled by spectroscopic  
844 imaging. *Stem Cells* (2015) <https://doi.org/10.1002/stem.1837>.
- 845 16. S. Yue, *et al.*, Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies  
846 human prostate cancer aggressiveness. *Cell Metab* **19**, 393–406 (2014).
- 847 17. L. Tirinato, *et al.*, Lipid droplets and ferritin heavy chain: A devilish liaison in human cancer cell  
848 radioresistance. *Elife* **10** (2021).
- 849 18. A. K. Cotte, *et al.*, Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports  
850 colorectal cancer chemoresistance. *Nat Commun* **9** (2018).
- 851 19. P. Liu, *et al.*, Rab-regulated interaction of early endosomes with lipid droplets. *Biochim Biophys Acta Mol*  
852 *Cell Res* **1773**, 784–793 (2007).
- 853 20. T. Thomou, *et al.*, Adipose-derived circulating miRNAs regulate gene expression in other tissues. *Nature*  
854 **542**, 450–455 (2017).
- 855 21. S. E. Flaherty, *et al.*, A lipase-independent pathway of lipid release and immune modulation by adipocytes.  
856 *Science* (1979) (2019) <https://doi.org/10.1126/science.aaw2586>.
- 857 22. M. Bordas, *et al.*, Optimized Protocol for Isolation of Small Extracellular Vesicles from Human and Murine  
858 Lymphoid Tissues. *Int J Mol Sci* (2020) <https://doi.org/10.3390/ijms21155586>.
- 859 23. A. de Maio, Extracellular heat shock proteins, cellular export vesicles, and the Stress Observation System: A  
860 form of communication during injury, infection, and cell damage It is never known how far a controversial  
861 finding will go! Dedicated to Ferruccio Ritossa <https://doi.org/10.1007/s12192-010-0236-4>.
- 862 24. C. Nisticò, *et al.*, Lipid droplet biosynthesis impairment through dgat2 inhibition sensitizes mcf7 breast  
863 cancer cells to radiation. *Int J Mol Sci* **22** (2021).
- 864 25. C. Corbet, *et al.*, TGFβ2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic  
865 spreading of cancer cells. *Nat Commun* **11** (2020).

- 866 26. I. Lazar, *et al.*, Adipocyte Exosomes Promote Melanoma Aggressiveness through Fatty Acid Oxidation: A  
867 Novel Mechanism Linking Obesity and Cancer. *Cancer Res* **76**, 4051–4057 (2016).
- 868 27. C. Crewe, P. E. Scherer, Intercellular and interorgan crosstalk through adipocyte extracellular vesicles. *Rev*  
869 *Endocr Metab Disord* (2021) <https://doi.org/10.1007/s11154-020-09625-x>.
- 870 28. M. Cerezo-Magaña, H. C. Christianson, T. H. van Kuppevelt, K. Forsberg-Nilsson, M. Belting, Hypoxic  
871 induction of exosome uptake through proteoglycan-dependent endocytosis fuels the lipid droplet phenotype  
872 in Glioma. *Molecular Cancer Research* **19**, 528–540 (2021).
- 873 29. I. Mylonis, G. Simos, E. Paraskeva, Hypoxia-Inducible Factors and the Regulation of Lipid Metabolism.  
874 *Cells* **8**, 214 (2019).
- 875 30. J. M. Heddleston, *et al.*, Hypoxia inducible factors in cancer stem cells. *Br J Cancer* **102**, 789–795 (2010).
- 876 31. M. Venturella, M. Criscuoli, F. Carraro, A. Naldini, D. Zocco, Interplay between hypoxia and extracellular  
877 vesicles in cancer and inflammation. *Biology (Basel)* **10** (2021).
- 878 32. J. J. Ban, M. Lee, W. Im, M. Kim, Low pH increases the yield of exosome isolation. *Biochem Biophys Res*  
879 *Commun* **461**, 76–79 (2015).
- 880 33. M. Logozzi, *et al.*, Microenvironmental pH and exosome levels interplay in human cancer cell lines of  
881 different histotypes. *Cancers (Basel)* **10** (2018).
- 882 34. X. Yu, S. L. Harris, A. J. Levine, The Regulation of Exosome Secretion: a Novel Function of the p53 Protein.  
883 *Cancer Res* **66**, 4795–802 (2006).
- 884 35. Y. Jin, Y. Tan, L. Chen, Y. Liu, Z. Ren, Reactive Oxygen Species Induces Lipid Droplet Accumulation in  
885 HepG2 Cells by Increasing Perilipin 2 Expression The Cooperative Innovation Center for Sustainable Pig  
886 Production. *International Journal of Molecular Sciences Article* <https://doi.org/10.3390/ijms19113445>.
- 887 36. E. Chiaradia, *et al.*, Extracellular vesicles under oxidative stress conditions: Biological properties and  
888 physiological roles. *Cells* **10** (2021).
- 889 37. L. Tirinato, *et al.*, ROS and Lipid Droplet accumulation induced by high glucose exposure in healthy colon  
890 and Colorectal Cancer Stem Cells. *Genes Dis* (2019) <https://doi.org/10.1016/j.gendis.2019.09.010>.
- 891 38. A. Da, *et al.*, Influence of high glucose on mesangial cell-derived exosome composition, secretion and cell  
892 communication <https://doi.org/10.1038/s41598-019-42746-1>.
- 893 39. Q.-J. Zhu, M. Zhu, X.-X. Xu, X.-M. Meng, Y.-G. Wu, Exosomes from high glucose-treated macrophages  
894 activate glomerular mesangial cells via TGF- $\beta$ 1/Smad3 pathway in vivo and in vitro  
895 <https://doi.org/10.1096/fj.201802427RRR>.
- 896 40. M. Takasugi, Emerging roles of extracellular vesicles in cellular senescence and aging. *Aging Cell* **17** (2018).
- 897 41. A. C. Flor, D. Wolfgeher, D. Wu, S. J. Kron, A signature of enhanced lipid metabolism, lipid peroxidation  
898 and aldehyde stress in therapy-induced senescence. *Cell Death Discov* **3** (2017).
- 899 42. B. D. Lehmann, *et al.*, Senescence-associated exosome release from human prostate cancer cells. *Cancer Res*  
900 **68**, 7864–7871 (2008).
- 901 43. X. Yu, T. Riley, A. J. Levine, The regulation of the endosomal compartment by p53 the tumor suppressor  
902 gene. *FEBS Journal* **276**, 2201–2212 (2009).
- 903 44. S. I. Wells, *et al.*, “Transcriptome signature of irreversible senescence in human papillomavirus-positive  
904 cervical cancer cells” (2003).
- 905 45. K. Sabapathy, K. Itahana, X. Chen, K. Laubach, J. Zhang, The p53 Family: A Role in Lipid and Iron  
906 Metabolism (2021) <https://doi.org/10.3389/fcell.2021.715974>.
- 907 46. L. Xi, *et al.*, Hypoxia-stimulated ATM activation regulates autophagy-associated exosome release from  
908 cancer-associated fibroblasts to promote cancer cell invasion. *J Extracell Vesicles* **10** (2021).
- 909 47. A. Muñoz-García, *et al.*, Hypoxia-induced HIF1 $\alpha$  activation regulates small extracellular vesicle release in  
910 human embryonic kidney cells. *Scientific Reports* | **12**, 1443 (123AD).
- 911 48. F. Bekbulat, *et al.*, RAB18 Loss Interferes With Lipid Droplet Catabolism and Provokes Autophagy Network  
912 Adaptations. *J Mol Biol* **432**, 1216–1234 (2020).
- 913 49. D. Xu, *et al.*, Rab18 promotes lipid droplet (LD) growth by tethering the ER to LDs through SNARE and  
914 NRZ interactions. *Journal of Cell Biology* **217**, 975–995 (2018).
- 915 50. C. Li, *et al.*, COPI – TRAPP II activates Rab18 and regulates its lipid droplet association . *EMBO J* **36**, 441–  
916 457 (2017).
- 917 51. M. E. Coulter, *et al.*, The ESCRT-III Protein CHMP1A Mediates Secretion of Sonic Hedgehog on a  
918 Distinctive Subtype of Extracellular Vesicles. *Cell Rep* **24**, 973-986.e8 (2018).
- 919 52. A. K. Gillingham, R. Sinka, I. L. Torres, K. S. Lilley, S. Munro, Toward a Comprehensive Map of the  
920 Effectors of Rab GTPases. *Dev Cell* **31**, 358 (2014).
- 921 53. B. D. M. Hodges, C. C. Wu, Proteomic insights into an expanded cellular role for cytoplasmic lipid droplets.  
922 *J Lipid Res* **51**, 262 (2010).
- 923 54. K. Deepa, *et al.*, Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian  
924 cancer phenotype: a novel mechanism linking STAT3/Rab proteins. *Oncogene* **37**, 3806–3821 (2018).
- 925 55. G. Augimeri, *et al.*, “Evidence for Enhanced Exosome Production in Aromatase Inhibitor-Resistant Breast  
926 Cancer Cells.”

- 927 56. S. Keerthikumar, *et al.*, “Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes.”  
928 57. M. Mathieu, *et al.*, Specificities of exosome versus small ectosome secretion revealed by live intracellular  
929 tracking of CD63 and CD9 <https://doi.org/10.1038/s41467-021-24384-2>.  
930 58. D. Tang, X. Chen, R. Kang, G. Kroemer, Ferroptosis: molecular mechanisms and health implications. *Cell*  
931 *Res* **31**, 107–125 (2021).  
932 59. B. Lu, *et al.*, Ferroptosis by Lipid Peroxidation: The Tip of the Iceberg? *Frontiers in Cell and Developmental*  
933 *Biology* | [www.frontiersin.org](http://www.frontiersin.org) **9**, 646890 (2021).  
934 60. I. Yanatori, D. R. Richardson, H. S. Dhekne, S. Toyokuni, F. Kishi, “CD63 is regulated by iron via the IRE-  
935 IRP system and is important for ferritin secretion by extracellular vesicles” (2021)  
936 <https://doi.org/10.1182/blood.2019000962>.  
937 61. C. W. Brown, *et al.*, Prolamin-2 Drives Ferroptosis Resistance by Stimulating Iron Export. *Dev Cell* **51**, 575-  
938 586.e4 (2019).  
939 62. E. Lengyel, L. Makowski, J. DiGiovanni, M. G. Kolonin, Cancer as a matter of fat: The crosstalk between  
940 adipose tissue and tumors. *Trends Cancer* **4**, 374 (2018).  
941 63. E. Clement, *et al.*, Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial  
942 metabolism and remodeling in tumor cells. *EMBO J* **39** (2020).  
943 64. I. Lazar, *et al.*, Adipocyte Exosomes Promote Melanoma Aggressiveness through Fatty Acid Oxidation: A  
944 Novel Mechanism Linking Obesity and Cancer. *Cancer Res* **76**, 4051–4057 (2016).  
945 65. L. Mutschelknaus, *et al.*, Radiation alters the cargo of exosomes released from squamous head and neck  
946 cancer cells to promote migration of recipient cells OPEN <https://doi.org/10.1038/s41598-017-12403-6>.  
947 66. R. Al-Abedi, S. T. Cagatay, A. Mayah, S. A. Brooks, M. Kadhim, Ionising radiation promotes invasive  
948 potential of breast cancer cells: The role of exosomes in the process. *Int J Mol Sci* **22** (2021).  
949 67. M. Todaro, *et al.*, CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon  
950 cancer metastasis. *Cell Stem Cell* **14**, 342–356 (2014).  
951 68. H. Li, *et al.*, The Sequence Alignment/Map format and SAMtools. *BIOINFORMATICS APPLICATIONS*  
952 *NOTE* **25**, 2078–2079 (2009).  
953 69. P. Ewels, M. Ns Magnusson, S. Lundin, M. K. Aller, Data and text mining MultiQC: summarize analysis  
954 results for multiple tools and samples in a single report <https://doi.org/10.1093/bioinformatics/btw354>.  
955 70. C. Sonesson, M. I. Love, M. D. Robinson, Differential analyses for RNA-seq: transcript-level estimates  
956 improve gene-level inferences. *F1000Research* 2016 4:1521 **4**, 1521 (2016).  
957 71. R. Patro, Salmon provides fast and bias-aware quantification of transcript expression (2017)  
958 <https://doi.org/10.1038/nmeth.4197>.  
959 72. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with  
960 DESeq2. *Genome Biol* **15**, 1–21 (2014).  
961  
962  
963  
964  
965  
966  
967  
968  
969